Antonio Pisani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7296337/publications.pdf

Version: 2024-02-01

181	6,940	66234	71532
papers	citations	42 h-index	76 g-index

183	183	183	7651
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Acetylcholine-mediated modulation of striatal function. Trends in Neurosciences, 2000, 23, 120-126.	4.2	400
2	Re-emergence of striatal cholinergic interneurons in movement disorders. Trends in Neurosciences, 2007, 30, 545-553.	4.2	400
3	Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. American Journal of Kidney Diseases, 2001, 38, 18-25.	2.1	242
4	Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. American Journal of Kidney Diseases, 1999, 33, 851-856.	2.1	228
5	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet, The, 2013, 382, 1485-1495.	6.3	218
6	Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2014, 25, 850-863.	3.0	199
7	Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain, 2009, 132, 2336-2349.	3.7	197
8	Insomnia in maintenance haemodialysis patients. Nephrology Dialysis Transplantation, 2002, 17, 852-856.	0.4	154
9	Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: Role of M₁ muscarinic receptors. Movement Disorders, 2014, 29, 1655-1665.	2.2	152
10	Activation of D2-Like Dopamine Receptors Reduces Synaptic Inputs to Striatal Cholinergic Interneurons. Journal of Neuroscience, 2000, 20, RC69-RC69.	1.7	144
11	Abnormal plasticity in dystonia: Disruption of synaptic homeostasis. Neurobiology of Disease, 2011, 42, 162-170.	2.1	144
12	Endogenous Serotonin Excites Striatal Cholinergic Interneurons via the Activation of 5-HT 2C, 5-HT6, and 5-HT7 Serotonin Receptors: Implications for Extrapyramidal Side Effects of Serotonin Reuptake Inhibitors. Neuropsychopharmacology, 2007, 32, 1840-1854.	2.8	122
13	Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinsonâ€™s disease. Journal of Neuroinflammation, 2012, 9, 188.	3.1	115
14	Centrality of Striatal Cholinergic Transmission in Basal Ganglia Function. Frontiers in Neuroanatomy, 2011, 5, 6.	0.9	113
15	Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrology Dialysis Transplantation, 2015, 30, 645-652.	0.4	113
16	Hyperkinetic disorders and loss of synaptic downscaling. Nature Neuroscience, 2016, 19, 868-875.	7.1	98
17	Acute Kidney Injury by Radiographic Contrast Media: Pathogenesis and Prevention. BioMed Research International, 2014, 2014, 1-21.	0.9	95
18	Metabolic effects of two low protein diets in chronic kidney disease stage 4-5--a randomized controlled trial. Nephrology Dialysis Transplantation, 2007, 23, 636-644.	0.4	93

#	Article	IF	Citations
19	Cholinergic Dysfunction Alters Synaptic Integration between Thalamostriatal and Corticostriatal Inputs in DYT1 Dystonia. Journal of Neuroscience, 2012, 32, 11991-12004.	1.7	93
20	Enzyme replacement therapy in patients with Fabry disease: State of the art and review of the literature. Molecular Genetics and Metabolism, 2012, 107, 267-275.	0.5	87
21	Prevention of Contrast-Induced Nephropathy through a Knowledge of Its Pathogenesis and Risk Factors. Scientific World Journal, The, 2014, 2014, 1-16.	0.8	86
22	The ischemic/nephrotoxic acute kidney injury and the use of renal biomarkers in clinical practice. European Journal of Internal Medicine, 2017, 39, 1-8.	1.0	85
23	Muscarinic IPSPs in rat striatal cholinergic interneurones. Journal of Physiology, 1998, 510, 421-427.	1.3	83
24	Role of Reactive Oxygen Species in Pathogenesis of Radiocontrast-Induced Nephropathy. BioMed Research International, 2013, 2013, 1-6.	0.9	82
25	Loss of Muscarinic Autoreceptor Function Impairs Long-Term Depression But Not Long-Term Potentiation in the Striatum. Journal of Neuroscience, 2008, 28, 6258-6263.	1.7	81
26	Sleep quality in renal transplant patients: a never investigated problem. Nephrology Dialysis Transplantation, 2005, 20, 194-198.	0.4	80
27	Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia. Neurobiology of Disease, 2009, 34, 133-145.	2.1	80
28	Developmental Profile of the Aberrant Dopamine D2 Receptor Response in Striatal Cholinergic Interneurons in DYT1 Dystonia. PLoS ONE, 2011, 6, e24261.	1.1	77
29	Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. BioMed Research International, 2017, 2017, 1-11.	0.9	75
30	First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1025-1031.	3.3	71
31	Atorvastatin Improves the Course of Ischemic Acute Renal Failure in Aging Rats. Journal of the American Society of Nephrology: JASN, 2004, 15, 901-909.	3.0	68
32	Effect of a Low- Versus Moderate-Protein Diet on Progression of CKD: Follow-up of a Randomized Controlled Trial. American Journal of Kidney Diseases, 2009, 54, 1052-1061.	2.1	64
33	Enzyme Replacement Therapy in Fabry Disease Patients Undergoing Dialysis: Effects on Quality of Life and Organ Involvement. American Journal of Kidney Diseases, 2005, 46, 120-127.	2.1	63
34	Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?. International Journal of Molecular Sciences, 2018, 19, 3726.	1.8	63
35	Dystonia and dopamine: From phenomenology to pathophysiology. Progress in Neurobiology, 2019, 182, 101678.	2.8	53
36	Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrology Dialysis Transplantation, 2012, 27, 3560-3567.	0.4	49

#	Article	IF	Citations
37	Sleep quality in patients with chronic renal failure: A 3-year longitudinal study. Sleep Medicine, 2008, 9, 240-246.	0.8	47
38	Inhibition of Ras/ERK1/2 signaling protects against postischemic renal injury. American Journal of Physiology - Renal Physiology, 2006, 290, F1408-F1415.	1.3	46
39	Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study. PLoS ONE, 2012, 7, e32533.	1.1	46
40	Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury. Clinical and Experimental Nephrology, 2013, 18, 424-31.	0.7	46
41	The potential use of biomarkers in predicting contrast-induced acute kidney injury. International Journal of Nephrology and Renovascular Disease, 2016, Volume 9, 205-221.	0.8	45
42	Long-term Effects of Octreotide on Liver Volume in Patients WithÂPolycystic Kidney and Liver Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1022-1030.e4.	2.4	45
43	Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrology Dialysis Transplantation, 2008, 23, 1628-1635.	0.4	44
44	Differential Activation of Signaling Pathways Involved in Cell Death, Survival and Inflammation by Radiocontrast Media in Human Renal Proximal Tubular Cells. Toxicological Sciences, 2011, 119, 408-416.	1.4	42
45	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. PLoS Medicine, 2019, 16, e1002777.	3.9	42
46	Synergy between the pharmacological chaperone 1â€deoxygalactonojirimycin and the human recombinant alphaâ€galactosidase A in cultured fibroblasts from patients with Fabry disease. Journal of Inherited Metabolic Disease, 2012, 35, 513-520.	1.7	40
47	A Clinical and Biochemical Analysis in the Differential Diagnosis of Idiopathic Normal Pressure Hydrocephalus. Frontiers in Neurology, 2015, 6, 86.	1.1	39
48	Neuroimaging in Fabry disease: current knowledge and future directions. Insights Into Imaging, 2018, 9, 1077-1088.	1.6	37
49	Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data. European Journal of Human Genetics, 2020, 28, 1662-1668.	1.4	37
50	MRI Characterization of Myocardial Tissue in Patients with Fabry's Disease. American Journal of Roentgenology, 2007, 188, 850-853.	1.0	36
51	Mycophenolic acid inhibits the phosphorylation of NF-Î¹B and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells. Chemico-Biological Interactions, 2010, 185, 253-262.	1.7	35
52	Prominent longitudinal strain reduction of left ventricular basal segments in treatment-naÃ¯ve Anderson-Fabry disease patients. European Heart Journal Cardiovascular Imaging, 2019, 20, 438-445.	0.5	34
53	Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study. Patient Preference and Adherence, 2014, 8, 73.	0.8	33
54	Differential Activation of Signaling Pathways by Lowâ€Osmolar and Isoâ€Osmolar Radiocontrast Agents in Human Renal Tubular Cells. Journal of Cellular Biochemistry, 2014, 115, 281-289.	1.2	33

#	Article	IF	Citations
55	Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media. BioMed Research International, 2014, 2014, 1-10.	0.9	32
56	Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review. BioMed Research International, 2017, 2017, 1-8.	0.9	32
57	Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2266-2273.	3.3	31
58	Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying Î±-Galactosidase A Mutation. Circulation: Cardiovascular Imaging, 2018, 11, e007019.	1.3	31
59	Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus. Journal of Neural Transmission, 2018, 125, 673-679.	1.4	31
60	Zaleplon Improves Sleep Quality in Maintenance Hemodialysis Patients. Nephron Clinical Practice, 2003, 94, c99-c103.	2.3	30
61	ECâ€MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMFâ€related gastrointestinal sideâ€effects. Fundamental and Clinical Pharmacology, 2009, 23, 617-624.	1.0	30
62	Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial. PLoS ONE, 2015, 10, e0118174.	1.1	30
63	Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis. Neuroradiology, 2017, 59, 563-570.	1.1	30
64	Genetic variants associated with Fabry disease progression despite enzyme replacement therapy. Oncotarget, 2017, 8, 107558-107564.	0.8	30
65	Genetic variants associated with gastrointestinal symptoms in Fabry disease. Oncotarget, 2016, 7, 85895-85904.	0.8	30
66	Hybrid positron emission tomography-magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Andersonâ€“Fabry disease: AFFINITY study group. European Heart Journal Cardiovascular Imaging, 2019, 20, 1004-1011.	0.5	28
67	6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial. Clinical and Experimental Nephrology, 2016, 20, 433-442.	0.7	27
68	Setting dialysis start at 6.0 ml/min/1.73 m2 eGFR--a study on safety, quality of life and economic impact. Nephrology Dialysis Transplantation, 2009, 24, 3434-3440.	0.4	26
69	Arginase inhibition slows the progression of renal failure in rats with renal ablation. American Journal of Physiology - Renal Physiology, 2003, 284, F680-F687.	1.3	25
70	Rhes regulates dopamine D2 receptor transmission in striatal cholinergic interneurons. Neurobiology of Disease, 2015, 78, 146-161.	2.1	25
71	Default mode network modifications in <scp>F</scp>abry disease: A restingâ€state fMRI study with structural correlations. Human Brain Mapping, 2018, 39, 1755-1764.	1.9	25
72	Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis. Molecular Genetics and Metabolism, 2020, 129, 132-141.	0.5	25

#	Article	IF	Citations
73	Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?. BMC Nephrology, 2018, 19, 282.	0.8	24
74	Coordinate high-frequency pattern of stimulation and calcium levels control the induction of LTP in striatal cholinergic interneurons. Learning and Memory, 2004, 11, 755-760.	0.5	23
75	Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. Journal of Nephrology, 2016, 29, 71-78.	0.9	22
76	Striatal and cerebellar vesicular acetylcholine transporter expression is disrupted in human DYT1 dystonia. Brain, 2021, 144, 909-923.	3.7	22
77	Reversal of radiocontrast medium toxicity in human renal proximal tubular cells by white grape juice extract. Chemico-Biological Interactions, 2015, 229, 17-25.	1.7	21
78	Effect of a Short-Course Treatment with Synbiotics on Plasma p-Cresol Concentration in Kidney Transplant Recipients. Journal of the American College of Nutrition, 2017, 36, 586-591.	1.1	21
79	Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrology Dialysis Transplantation, 2018, 33, 318-323.	0.4	21
80	Optical Coherence Tomography Angiography Findings in Fabry Disease. Journal of Clinical Medicine, 2019, 8, 528.	1.0	21
81	Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. BioMed Research International, 2015, 2015, 1-8.	0.9	20
82	What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review. International Journal of Surgery, 2016, 28, S172-S176.	1.1	20
83	Molecular and clinical studies in five index cases with novel mutations in the GLA gene. Gene, 2016, 578, 100-104.	1.0	20
84	Enhanced mu opioid receptorâ€“dependent opioidergic modulation of striatal cholinergic transmission in DYT1 dystonia. Movement Disorders, 2018, 33, 310-320.	2.2	20
85	Therapeutic advances in ADPKD: the future awaits. Journal of Nephrology, 2021, , 1.	0.9	20
86	A pilot study of circulating microRNAs as potential biomarkers of Fabry disease. Oncotarget, 2018, 9, 27333-27345.	0.8	20
87	Antiproteinuric effect of add-on paricalcitol in Fabry disease patients: a prospective observational study. Nephrology Dialysis Transplantation, 2015, 30, 661-666.	0.4	19
88	Alterations of functional connectivity of the motor cortex in Fabry disease. Neurology, 2017, 88, 1822-1829.	1.5	19
89	Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review. Aging Clinical and Experimental Research, 2017, 29, 73-78.	1.4	19
90	Early Biomarkers of Fabry Nephropathy: A Review of the Literature. Nephron, 2019, 143, 274-281.	0.9	19

#	Article	IF	Citations
91	Nutritional treatment in chronic kidney disease: the concept of nephroprotection. Clinical and Experimental Nephrology, 2015, 19, 161-167.	0.7	18
92	Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial. Clinical and Experimental Nephrology, 2018, 22, 529-538.	0.7	18
93	Glomerular Hyperfiltration: An Early Marker of Nephropathy in Fabry Disease. Nephron, 2019, 141, 10-17.	0.9	18
94	Diagnosis and Management of Cardiovascular Involvement in Fabry Disease. Heart Failure Clinics, 2022, 18, 39-49.	1.0	18
95	Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995â€“2019. Journal of Nephrology, 2020, 33, 569-581.	0.9	17
96	A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report. BMC Cardiovascular Disorders, 2012, 12, 39.	0.7	16
97	Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. American Journal of Physiology - Renal Physiology, 2014, 306, F1243-F1250.	1.3	16
98	Quercetin protects against radiocontrast medium toxicity in human renal proximal tubular cells. Journal of Cellular Physiology, 2018, 233, 4116-4125.	2.0	16
99	DNA methylation impact on Fabry disease. Clinical Epigenetics, 2021, 13, 24.	1.8	16
100	Experimental Models of Dystonia. International Review of Neurobiology, 2011, 98, 551-572.	0.9	15
101	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 1177-1190.	2.2	14
102	Fanconi syndrome with lysinuric protein intolerance. CKJ: Clinical Kidney Journal, 2014, 7, 599-601.	1.4	13
103	Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by 123I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 729-739.	3.3	13
104	Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis. Brain and Behavior, 2018, 8, e01121.	1.0	13
105	Layerâ€specific longitudinal strain in Andersonâ€“Fabry diseaseÂat diagnosis: A speckle tracking echocardiography analysis. Echocardiography, 2019, 36, 1273-1281.	0.3	13
106	Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial. International Journal of Cardiology, 2019, 275, 145-151.	0.8	13
107	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases. PLoS ONE, 2020, 15, e0233050.	1.1	13
108	Does left ventricular function predict cardiac outcome in Andersonâ€“Fabry disease?. International Journal of Cardiovascular Imaging, 2021, 37, 1225-1236.	0.7	13

#	Article	IF	Citations
109	Reduced Intracranial Volume in Fabry Disease: Evidence of Abnormal Neurodevelopment?. Frontiers in Neurology, 2018, 9, 672.	1.1	12
110	Oral SucrosomialÂ® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis. BMC Nephrology, 2020, 21, 57.	0.8	12
111	Renal Sympatheticâ€Nerve Ablation for Uncontrolled Hypertension in a Patient With Singleâ€Kidney Autosomal Dominant Polycystic Kidney Disease. Journal of Clinical Hypertension, 2014, 16, 385-386.	1.0	11
112	Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature. Genetics in Medicine, 2017, 19, 275-282.	1.1	11
113	Impact of COVID-19 pandemic on patients with Fabry disease: An Italian experience. Molecular Genetics and Metabolism, 2020, 131, 124-125.	0.5	11
114	Effects of mycophenolate mofetil on acute ischaemia-reperfusion injury in rats and its consequences in the long term. Nephrology Dialysis Transplantation, 2010, 25, 1443-1450.	0.4	10
115	Electrophysiology of 5-HT6 Receptors. International Review of Neurobiology, 2010, 94, 111-128.	0.9	10
116	The Choice of the Iodinated Radiographic Contrast Media to Prevent Contrast-Induced Nephropathy. Advances in Nephrology, 2014, 2014, 1-11.	0.2	10
117	Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study. Parkinsonism and Related Disorders, 2018, 57, 27-32.	1.1	10
118	New insights from the application of the FAbry STabilization indEX in a large population of Fabry cases. CKJ: Clinical Kidney Journal, 2019, 12, 65-70.	1.4	10
119	Vesicular Acetylcholine Transporter Alters Cholinergic Tone and Synaptic Plasticity in <scp>DYT1</scp> Dystonia. Movement Disorders, 2021, 36, 2768-2779.	2.2	10
120	Diagnostic clues for the diagnosis of nonsarcomeric hypertrophic cardiomyopathy (Phenocopies): Amyloidosis, fabry disease, and mitochondrial disease. Journal of Cardiovascular Echography, 2018, 28, 120.	0.1	10
121	Nephrotic syndrome and autosomal dominant polycystic kidney disease. CKJ: Clinical Kidney Journal, 2012, 5, 508-511.	1.4	9
122	Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease. BMC Research Notes, 2015, 8, 711.	0.6	9
123	The Retinal Vessel Density as a New Vascular Biomarker in Multisystem Involvement in Fabry Disease: An Optical Coherence Tomography Angiography Study. Journal of Clinical Medicine, 2020, 9, 4087.	1.0	9
124	The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts. Orphanet Journal of Rare Diseases, 2020, 15, 86.	1.2	9
125	Simultaneous multicystic kidney and Anderson-Fabry disease: 2 separate entities or same side of the coin. Journal of Nephrology, 2011, 24, 806-808.	0.9	9
126	RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study. Frontiers in Cardiovascular Medicine, 2022, 9, 824095.	1.1	9

#	Article	IF	Citations
127	Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report. BMC Nephrology, 2019, 20, 426.	0.8	8
128	The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials. Scientific Reports, 2021, 11, 23500.	1.6	8
129	The impact of haemoglobin on the quality of sleep in haemodialysis patients: which is the truth?. Nephrology Dialysis Transplantation, 2003, 18, 1947-1948.	0.4	7
130	Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. Internal and Emergency Medicine, 2017, 12, 1059-1067.	1.0	7
131	ADPKD and metformin: from bench to bedside. Clinical and Experimental Nephrology, 2019, 23, 1341-1342.	0.7	7
132	Predictive effect of salt intake on patient and kidney survival in non-dialysis CKD: competing risk analysis in older versus younger patients under nephrology care. Nephrology Dialysis Transplantation, 2020, 36, 2232-2240.	0.4	7
133	Microstructural damage of the cortico-striatal and thalamo-cortical fibers in Fabry disease: a diffusion MRI tractometry study. Neuroradiology, 2020, 62, 1459-1466.	1.1	7
134	Role of serial cardiac 18F-FDG PET-MRI in Andersonâ€“Fabry disease: a pilot study. Insights Into Imaging, 2021, 12, 124.	1.6	7
135	Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: â€œCan the Promise Be Kept?â€. International Journal of Molecular Sciences, 2021, 22, 12590.	1.8	7
136	Association between Left Atrial Deformation and Brain Involvement in Patients with Anderson-Fabry Disease at Diagnosis. Journal of Clinical Medicine, 2020, 9, 2741.	1.0	6
137	Acute Kidney Injury in COVID-19 Pandemic. Nephron, 2020, 144, 345-346.	0.9	6
138	COVID-19 Experience in Hemodialysis Patients: A Cue for Therapeutic Heparin-Based Strategies?. Nephron, 2020, 144, 383-385.	0.9	6
139	Focal reduction in left ventricular 123I-metaiodobenzylguanidine uptake and impairment in systolic function in patients with Anderson-Fabry disease. Journal of Nuclear Cardiology, 2021, 28, 641-649.	1.4	6
140	Circulating miR-184 is a potential predictive biomarker of cardiac damage in Andersonâ€“Fabry disease. Cell Death and Disease, 2021, 12, 1150.	2.7	6
141	Towards a new era for dystonia, a high priority for biomedical research. Neurobiology of Disease, 2011, 42, 125-126.	2.1	5
142	Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and agalsidase alpha in cultured fibroblasts from patients with Fabry disease. Journal of Inherited Metabolic Disease, 2014, 37, 145-146.	1.7	5
143	Pituitary function and morphology in Fabry disease. Endocrine, 2015, 50, 483-488.	1.1	5
144	Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?. Genetics in Medicine, 2015, 17, 21-23.	1.1	5

#	Article	IF	Citations
145	Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients. Data in Brief, 2018, 21, 2075-2081.	0.5	5
146	MALDI imaging in Fabry nephropathy: a multicenter study. Journal of Nephrology, 2020, 33, 299-306.	0.9	5
147	Left ventricular radial strain impairment precedes hypertrophy in Andersonâ€“Fabry disease. International Journal of Cardiovascular Imaging, 2020, 36, 1465-1476.	0.7	5
148	Motor involvement in Fabry disease. Molecular Genetics and Metabolism Reports, 2018, 14, 43.	0.4	4
149	Multiple sclerosis and fabry Disease, two sides of the coin? The case of an Italian family. Multiple Sclerosis and Related Disorders, 2018, 26, 164-167.	0.9	4
150	Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol. Molecular Genetics & Genomic Medicine, 2021, 9, e1659.	0.6	4
151	The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease. European Radiology, 2022, , 1.	2.3	4
152	Clinical treatment of polycystic kidney disease (APKD): do we need further suggestions from rodents?. Nephrology Dialysis Transplantation, 2011, 26, 2065-2066.	0.4	3
153	Pleural effusion in peritoneal dialysis: overload or leakage?. Clinical and Experimental Nephrology, 2013, 17, 907-907.	0.7	3
154	Catheter-Based Renal Denervation in ADPKD: Just for Pain Control?. American Journal of Kidney Diseases, 2014, 64, 999.	2.1	3
155	Multimodality imaging approach to Fabry cardiomyopathy: Any role for nuclear cardiology?. Journal of Nuclear Cardiology, 2022, 29, 1439-1445.	1.4	3
156	Potential resistance to SARS-CoV-2 infection in lysosomal storage disorders. CKJ: Clinical Kidney Journal, 2021, 14, 1488-1490.	1.4	3
157	The Role of Immunosuppressive Therapy in Aneurysmal Degeneration of Hemodialysis Fistulas in Renal Transplant Patients. Annals of Vascular Surgery, 2021, 74, 21-28.	0.4	3
158	Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease. Future Cardiology, 2017, 13, 521-527.	0.5	2
159	Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study. Journal of the Neurological Sciences, 2020, 412, 116782.	0.3	2
160	Nonvascular Parkinsonism in Fabry Disease: Results From Magnetic Resonance and Dopamine Transporter Imaging. Journal of Neuropathology and Experimental Neurology, 2021, 80, 476-479.	0.9	2
161	A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency. Journal of Nephrology, 2012, 25, 582-585.	0.9	2
162	Polycystic horseshoe kidney. Clinical and Experimental Nephrology, 2013, 17, 905-906.	0.7	1

#	Article	IF	Citations
163	Endothelial-mediated coronary flow reserve in patients with Andersonâ€“Fabry disease. International Journal of Cardiology, 2014, 177, 1059-1060.	0.8	1
164	Arterial aneurysms: autosomal dominant polycystic kidney disease, Marfan syndrome or both?. Clinical and Experimental Nephrology, 2014, 18, 672-673.	0.7	1
165	An unusual case of tuberous sclerosis incidentally discovered in adulthood: case report and review of the literature. Acta Radiologica Open, 2018, 7, 205846011880632.	0.3	1
166	New insights for early assessment of cardiac involvement in Anderson-Fabry disease. Journal of Nuclear Cardiology, 2021, 28, 2500-2502.	1.4	1
167	Early Predictors of Arteriovenous Fistula Maturation: Preoperative Arterial Diameter Alone Is Not Enough. Journal of the American Society of Nephrology: JASN, 2020, 31, 2226-2228.	3.0	1
168	Darbepoetin alfa reduces cell death due to radiocontrast media in human renal proximal tubular cells. Toxicology Reports, 2021, 8, 816-821.	1.6	1
169	How relevant is the cholinergic system in DYT1 dystonia?. Basal Ganglia, 2012, 2, 227-230.	0.3	0
170	Atrial septum aneurysm: an unusual manifestation in ADPKD?. Clinical and Experimental Nephrology, 2015, 19, 1206-1207.	0.7	0
171	Author response: Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study. Neurology, 2017, 89, 1842-1843.	1.5	0
172	Parapelvic Cysts: A Suspicious Feature of Fabry Disease. Giornale De Techniche Nefrologiche & Dialitiche, 2017, 29, 101-102.	0.1	0
173	Animal Models of Dystonia. , 0, , 49-52.		0
174	Renal Denervation for Resistant Hypertension: Time to Improve Patient Selection. The Lesson From ADPKD. Frontiers in Medicine, 2020, 7, 604384.	1.2	0
175	Cholinergic Interneuron and Parkinsonism. , 2009, , 1-11.		0
176	Title is missing!. , 2020, 15, e0233050.		0
177	Title is missing!. , 2020, 15, e0233050.		0
178	Title is missing!. , 2020, 15, e0233050.		0
179	Title is missing!. , 2020, 15, e0233050.		0
180	Title is missing!. , 2020, 15, e0233050.		0

#	Article	IF	Citations
181	Title is missing!. , 2020, 15, e0233050.		0